Roboearth – Lifestyle
Author:
Ocugen
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
May 4, 2026
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
April 29, 2026
Ocugen to Present at April 2026 Investor and Industry Conferences
April 23, 2026
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
April 1, 2026
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
March 24, 2026
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
March 23, 2026